Drug Approval | February 19, 2022
Amneal expands injectables portfolio with four new products
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Subscribe To Our Newsletter & Stay Updated
